Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

Simply Wall St.08-08 16:29

In the past week, ImmunityBio, Inc. reported second-quarter 2026 results showing revenue of US$51.24 million versus US$26.43 million a year earlier, alongside a wider net loss of US$230.38 million and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657627723?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-08 16:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657627723","market":"hk","top_or_hot":-1,"title":"Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next","media":"Simply Wall St.","content":"<div>\n<p>In the past week, ImmunityBio, Inc. reported second-quarter 2026 results showing revenue of US$51.24 million versus US$26.43 million a year earlier, alongside a wider net loss of US$230.38 million and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-is-up-66-after-anktivas-uae-expansion-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-08 16:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-is-up-66-after-anktivas-uae-expansion-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the past week, ImmunityBio, Inc. reported second-quarter 2026 results showing revenue of US$51.24 million versus US$26.43 million a year earlier, alongside a wider net loss of US$230.38 million and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-is-up-66-after-anktivas-uae-expansion-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UAE","symbol_name":"iShares MSCI UAE ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-is-up-66-after-anktivas-uae-expansion-a","article_id":"2657627723","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-is-up-66-after-anktivas-uae-expansion-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2657627723","pubTimestamp":1786177755,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In the past week, ImmunityBio, Inc. reported second-quarter 2026 results showing revenue of US$51.24 million versus US$26.43 million a year earlier, alongside a wider net loss of US$230.38 million and basic loss per share from continuing operations of US$0.22, up from US$0.10.\nA few days earlier, the company received broad UAE marketing authorization for its immunotherapy ANKTIVA across bladder and lung cancer indications, expanding its regulatory footprint to 34 countries and highlighting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"UAE":"iShares MSCI UAE ETF","IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"为什么 ImmunityBio (IBRX) 在 ANKTIVA 的阿联酋扩张和第二季度业绩好坏参半后上涨了 6.6%--以及下一步是什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UAE":1.5,"IBRX":1.5},"content_text":"In the past week, ImmunityBio, Inc. reported second-quarter 2026 results showing revenue of US$51.24 million versus US$26.43 million a year earlier, alongside a wider net loss of US$230.38 million and basic loss per share from continuing operations of US$0.22, up from US$0.10. A few days earlier, the company received broad UAE marketing authorization for its immunotherapy ANKTIVA across bladder and lung cancer indications, expanding its regulatory footprint to 34 countries and highlighting the contrast between growing commercial reach and very large ongoing losses. Next, we’ll examine how ANKTIVA’s expanded UAE approvals across bladder and lung cancer could reshape ImmunityBio’s investment narrative and future expectations. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementImmunityBio Investment Narrative RecapTo own ImmunityBio, you need to believe ANKTIVA can grow from a single core product into a broader oncology platform while the company absorbs very large ongoing losses. The UAE approvals and stronger revenue do not change the key short term focus, which remains regulatory progress for additional bladder cancer uses and the risk that expanding trials and commercialization keep net losses elevated for longer than some investors may expect. The UAE decision to authorize ANKTIVA for both BCG unresponsive non muscle invasive bladder cancer and metastatic non small cell lung cancer is the most relevant development here. It extends the drug’s reach to 34 countries, building on earlier Saudi approvals and giving more real world context for how quickly new markets might contribute, and how that interacts with the existing catalyst around future label expansions in bladder cancer. Yet in contrast to the recent approvals, investors should still be aware that sustained heavy losses and dependence on ANKTIVA... Read the full narrative on ImmunityBio (it's free!)ImmunityBio's narrative projects $1.6 billion revenue and $673.2 million earnings by 2029. This requires 125.9% yearly revenue growth and about a $1.53 billion earnings increase from -$854.5 million today.Uncover how ImmunityBio's forecasts yield a $13.00 fair value, a 70% upside to its current price.Exploring Other PerspectivesIBRX 1-Year Stock Price Chart Some of the lowest estimate analysts were already assuming about US$1.7 billion in 2029 revenue and US$719.9 million in earnings, yet they still warned that reliance on ANKTIVA and country by country approvals in lung cancer could limit upside; the new UAE authorization might eventually shift those views, but you should recognize how far apart expectations can be before deciding which narrative you find more realistic.Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth over 6x more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Every day counts. These free picks are already gaining attention. See them before the crowd does:The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657627723","isCrawlerRequest":true}